CV/COS Webinar: Applications and Future Directions

At Carevive, we believe that data is a powerful tool that can revolutionize cancer care. In this video, we explore the diverse applications of our data and how it can drive better outcomes for patients and clinicians alike.

One crucial application lies in supporting patient-reported outcome (PRO) measure selection for clinical trial planning. Our real-time data from a standard-of-care population offers contemporary insights into FDA-relevant domains. Unlike historical trial data that can quickly become outdated due to rapidly evolving oncology standards, our data ensures up-to-date and relevant measure selection.

Furthermore, our data serves as a bridge between real-world data and clinical trials. With PRO measures similar in domain coverage and assessment frequency, comparing patient experiences on treatment becomes more comparable, enabling apples-to-apples comparisons for efficacy, safety, and tolerability assessments.

The ability to analyze population-level differences and individual time course changes remotely is yet another valuable aspect of our data. This feature proves instrumental in profiling the impact of care management interventions and predicting risk factors.

Recent Episodes

In this episode of Inside Restoration & Recovery, host Martha Lewis welcomes Jason McClaren, Director of Facilities Operations at Reunion Rehabilitation Hospitals, to discuss the critical advantage of partnering with a restoration team experienced in healthcare. A former firefighter and military veteran, Jason has spent the last decade managing safety, risk, and emergency preparedness…

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…